.jpeg)
Price of Ruxolitinib after inclusion in medical insurance
The original drug Ruxolitinib has been launched in China and is covered by Class B medical insurance, but it can only be used by patients who meet the indications, including patients with intermediate-risk or high-risk primary myelofibrosis (PMF), myelofibrosis secondary to polycythemia vera (PPV-MF) or myelofibrosis secondary to essential thrombocythemia (PET-MF). The common name is ruxolitinib phosphate tablets, SpecificationsThe price of 5mg*60 tablets per box may be around 3,000 RMB. Different regions have different reimbursement ratios, and the price after reimbursement may be different. Domestic pharmacies or hospitals may sell this drug.
[ 免责声明 ] 本页面内容来自公开渠道（如FDA官网、Drugs官网、原研药厂官网等），仅供持有医疗专业资质的人员用于医学药学研究参考，不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市，不适用于中国境内销售和使用。如需治疗，请咨询正规医疗机构。本站不提供药品销售或代购服务。
